The core activity of Centenara Labs AG is the development and investment in therapies that combat age-related diseases such as cancer, muscle weakness, vision loss, and cognitive impairments. The company focuses on researching and developing medications that address the so-called "Hallmarks of Aging" to improve the health and well-being of older people and extend their lifespan.
AI-generated
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Industry:Research & DevelopmentPharmaceutical Industry
✓ Offered8
Development and investment in therapies for age-related diseases
Development and investment in therapies for age-related diseases, expansion of a pipeline of therapeutics, supporting researchers in translating scientific discoveries into medicines.
Development of senescence therapeutics
Development of new approaches for the targeted removal of aging cells with applications in cancer, fibrosis and age-related diseases; preclinical pipeline with RejuverSen and RST programmes.
Development of telomer therapeutics
Development of therapies to restore telomere function in age-related disorders and rare genetic diseases; preclinical programme with CCT-001.
Development of vascular neurotherapeutics
Development of therapies to restore cerebral blood supply and improve CNS function in neurodegenerative and age-related diseases; discovery programme with CVT-001.
Building and investing in portfolio companies
Building portfolio companies with early therapeutics companies, co-founding with scientific entrepreneurs and investing in diversified projects.
Knowledge
No knowledge articles yet
Once Centenara Labs AG has claimed this profile, we'll publish editorial articles and case studies here together.